Galenghui October 15th | HaiChuang Pharmaceuticals (688302.SH) announced that it has received the Drug Clinical Trial Approval Notice approved and issued by the China National Medical Products Administration Drug Evaluation Center, approving the HP568 tablets for the clinical trial of treating late-stage breast cancer with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative (ER+/HER2- late-stage breast cancer). As of the date of this announcement, there are no similar PROTAC products approved for marketing domestically or internationally.
海创药业(688302.SH)：口服PROTAC药物HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验获得药物临床试验批准通知书
Haisco Pharmaceutical Co., Ltd. (688302.SH): The oral PROTAC drug HP568 tablets for the clinical trial of ER+/HER2- advanced breast cancer obtained the Drug Clinical Trial Approval Letter.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha